KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Invested Capital (2016 - 2025)

Historic Invested Capital for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $85.1 million.

  • Nektar Therapeutics' Invested Capital rose 7405.7% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 7405.7%. This contributed to the annual value of $60.7 million for FY2024, which is 5363.13% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Invested Capital of $85.1 million as of Q3 2025, which was up 7405.7% from -$24.2 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Invested Capital peaked at $994.5 million during Q1 2021, and registered a low of -$24.2 million during Q2 2025.
  • Its 5-year average for Invested Capital is $333.9 million, with a median of $197.0 million in 2023.
  • The largest annual percentage gain for Nektar Therapeutics' Invested Capital in the last 5 years was 7405.7% (2025), contrasted with its biggest fall of 13038.22% (2025).
  • Quarter analysis of 5 years shows Nektar Therapeutics' Invested Capital stood at $679.5 million in 2021, then crashed by 46.04% to $366.6 million in 2022, then crashed by 64.27% to $131.0 million in 2023, then tumbled by 53.63% to $60.7 million in 2024, then soared by 40.09% to $85.1 million in 2025.
  • Its Invested Capital stands at $85.1 million for Q3 2025, versus -$24.2 million for Q2 2025 and $13.7 million for Q1 2025.